Evidence map›Paper›PMID 26303131›Full record

SynthesisThe American journal of gastroenterology2015

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

L Peyrin-Biroulet, W Sandborn, B E Sands, W Reinisch, W Bemelman, R V Bryant, G D'Haens, I Dotan, M Dubinsky, B Feagan and 28 more

2 registry-linked trialsAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 805 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
805citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03885713 phase4completednot on this mapstarted 2019, after this paper: background citation

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches

TypeinterventionalSponsorFundación de Investigación Biomédica - Hospital Universitario de La PrincesaRan2019 to 2024Enrolled180ConditionsInflammatory Bowel Diseases, Crohn Disease, Ulcerative ColitisArmsInfliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
NCT05313620 phase4recruitingnot on this mapstarted 2022, after this paper: background citation

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

TypeinterventionalSponsorFundación de Investigación Biomédica - Hospital Universitario de La PrincesaRan2022 to 2025Enrolled30ConditionsUlcerative Colitis, ThromboembolismArmsTofacitinib, Infliximab Adalimumab y Golimumab
3 · Its place in the literature

Who cites it

805 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Quality indicators for colonoscopy.Gastrointestinal endoscopy · 2024
    Guideline
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Review

745 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

L Peyrin-BirouletINSERM Unité 954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, University of Lorraine, Houdemont, France.
W SandbornDivision of Gastroenterology, University of California San Diego, La Jolla, California, USA.
B E SandsHenry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
W ReinischMcMaster University, Hamilton, Ontario, Canada.
W BemelmanDepartment of Surgery, Academic Medical Center, Amsterdam, The Netherlands.
R V BryantTranslational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
G D'HaensDepartment of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands.
I DotanInflammatory Bowel Disease Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
M DubinskyDivision of Pediatric Gastroenterology and Hepatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
B FeaganUniversity of Western Ontario, London, Ontario, Canada.
G FiorinoInflammatory Bowel Disease Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy.
R GearryDepartment of Medicine, University of Otago, Christchurch, New Zealand.
S KrishnareddyColumbia University Division of Digestive and Liver Diseases, New York, New York, USA.
P L LakatosFirst Department of Medicine, Semmelweis University, Budapest, Hungary.
E V LoftusDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
P MarteauAP-HP, Department of Digestive Diseases, Hôpital Lariboisière Medicosurgical and University Denis Diderot, Paris, France.
P MunkholmNorth Zealand Hospital, Capital Region, University of Copenhagen, Copenhagen, Denmark.
T B MurdochInflammatory Bowel Disease Group, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
I OrdásDepartment of Gastroenterology, Hospital Clinic of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.
R PanaccioneInflammatory Bowel Disease Clinic University of Calgary, Calgary, Alberta, Canada.
R H RiddellDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
J RuelDivision of Gastroenterology, CHU Sherbrooke, Sherbrooke, Quebec, Canada.
D T RubinSection of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, Illinois, USA.
M SamaanDepartment of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands.
C A SiegelDartmouth-Hitchcock Inflammatory Bowel Disease Center, Hanover, New Hampshire, USA.
M S SilverbergZane Cohen Centre for Digestive Diseases, Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
J StokerDepartment of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
S SchreiberDepartment of General Internal Medicine, Christian-Albrechts-University, University Hospital Schleswig Holstein, Kiel, Germany.
S TravisTranslational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
G Van AsscheDivision of Gastroenterology, University of Leuven, Leuven, Belgium.
S DaneseInflammatory Bowel Disease Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy.
J PanesDepartment of Gastroenterology, Hospital Clinic of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.
G BouguenService des Maladies de l'Appareil Digestif et INSERM U991, CHU Pontchaillou et Université de Rennes 1, Rennes, France.
S O'DonnellZane Cohen Centre for Digestive Diseases, Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
B ParienteDepartment of Hepato-Gastroenterology, Claude Huriez Hospital, Université Lille Nord de France, Lille, France.
S WinerDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
S HanauerNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
J-F ColombelHenry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process.

methodsA Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely).

resultsThe group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target.

conclusionsEvidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.

Indexed as

Disease ManagementPractice Guidelines as TopicHumansInflammatory Bowel DiseasesRemission Induction

Identifiers

PMID26303131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.